Date: Apr 14, 2018 09:00 AM - 11:30 AM
Registration closes on Apr 14, 2018 08:50 AM
The disclosure policies of the SIUE School of Pharmacy Office of Continuing Professional Education requires all persons in a position to control content to disclose any relevant financial relationships with commercial interests. If a conflict is identified, the Office of Professional Continuing Education will initiate a process for resolving the conflict. The existence of relationships does not necessarily imply bias or lessen the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The persons required to disclose conflicts include all course faculty, the SIUE CPE administrator, all activity planners and all reviewers. The relevant commercial financial relationships or affiliations must have occured over the past 12 months.
The participant must provide the correct NABP ePID number/DOB combination in their electronic profile. All CPE evaluations must be completed within 60 days of activity. It is the participant's responsibility to check that their credit records are correct within the 60 day period after completion of the activity. Log in to CPE Monitor at www.mycpemonitor.net to view a list of all ACPE-accredited activities you have taken. Any discrepancies must be resolved with the CPE Provider directly and in a timely manner.
Requirements for CE Credit
- Describe the current trends in pharmacy legislation in the Illinois General Assembly
- Describe the timeline and revisions to the Administrative Rules of the Pharmacy Practice Act and the Controlled Substance Act
Garth K Reynolds
Disclosure : Garth Reynolds has completed and submitted the SIUE School of Pharmacy Continuing Pharmacy Education Form for Disclosure of Potential Conflicts of Interest and none were reported.
- Identify the role of hormonal therapies in the management of hormone-receptor positive breast cancer.
- Summarize emerging evidence regarding the use of hormonal therapies in breast cancer
- Explain the mechanism of action of cyclin dependent kinase inhibitors
- Identify the role of cyclin dependent kinase inhibitors in the treatment of advanced hormone-receptor positive breast cancer
- Compare and contrast the safety profiles of palbociclib, ribociclib, and abemaciclib
Keith Hecht, Pharm.D., BCOP
Brief Bio : Dr. Hecht is a clinical associate professor in the Department of Pharmacy Practice. Before joining SIUE, Dr. Hecht served as an assistant professor of Pharmacy Practice at the University of Southern Nevada College of Pharmacy. Dr. Hecht received his B.S. (2000) and Doctorate of Pharmacy (2001) from St. Louis College of Pharmacy. Subsequently, he completed a pharmacy practice residency and an oncology specialty residency at the University of Kentucky Chandler Medical Center, where he also obtained a certificate for scholarship of teaching and learning. He has been a board-certified oncology pharmacy specialist since 2004. In addition to his faculty appointment at SIUE, Dr. Hecht also provides clinical services in inpatient oncology at St. John’s Mercy Medical Center. Dr. Hecht is interested in various areas of oncology pharmacy practice including supportive care, patient education, and optimizing patient adherence with oncology medications. His research areas of interest include growth factor support, anti-infective use, and regimen optimization in oncology patients.